


Antimicrobial Peptides

Discovery, Design and Novel Therapeutic Strategies

Edited by Guangshun Wang



amcm
18

ADVANCES IN MOLECULAR AND CELLULAR MICROBIOLOGY


www.cabi.org

Contents

Contributors	xi
Preface	xiii
Introduction	xv
<i>Michael Zasloff</i>	

PART I: NATURAL ANTIMICROBIAL PEPTIDES: NOMENCLATURE, CLASSIFICATION AND INTERESTING TEMPLATES FOR PEPTIDE ENGINEERING

1 A Database View of Naturally Occurring Antimicrobial Peptides: Nomenclature, Classification and Amino Acid Sequence Analysis	1
<i>Guangshun Wang, Xia Li and Michael Zasloff</i>	
1.1 Database Scope and Overview	2
1.2 Nomenclature of Antimicrobial Peptides	3
1.2.1 Peptide-based method	4
1.2.2 Source-based method	4
1.2.3 Source and peptide combined method	4
1.3 Annotation and Classification of Antimicrobial Peptides	5
1.3.1 Source organisms and peptide family classification	5
1.3.2 Classification based on biological activities	8
1.3.3 Classification based on peptide characteristics	9
1.3.4 Peptide-binding targets and mechanisms of action	14
1.4 Amino Acid Sequence Analysis of Antimicrobial Peptides	15
1.5 Concluding Remarks	17
2 Lantibiotic-related Research and the Application Thereof	22
<i>Brian Healy, Jim O'Mahony, Colin Hill, Paul D. Cotter and R. Paul Ross</i>	
2.1 Introduction to Bacteriocins	22
2.2 Biosynthesis and Post-translational Modifications	23
2.3 Classification	24
2.4 Lantibiotic Subgroups: Biology, Structure and Mode of Action	25
2.4.1 Nisin-like lantibiotics	25
2.4.2 Epidermin-like lantibiotics	26

2.4.3	Planosporicin- and streptin-like lantibiotics	27
2.4.4	Pep5-like peptides	27
2.4.5	Lacticin 481-like lantibiotics	27
2.4.6	Mersacidin-like lantibiotics	28
2.4.7	LtnA2-like peptides	28
2.4.8	Other type II lantibiotics	28
2.5	Current and Future Use of Lantibiotics for Food Applications	29
2.6	Lantibiotics and Their Medical Applications	30
2.7	Engineering of Lantibiotics	30
2.8	Screening for New Lantibiotics	31
2.9	Concluding Remarks and Perspectives	32
3	Antimicrobial Peptides in Plants	40
	<i>Quentin Kaas, Jan-Christoph Westermann, Sónia Troeira Henriques and David J. Craik</i>	
3.1	Introduction to Plant Antimicrobial Peptides	40
3.1.1	Lipid-transfer proteins	41
3.1.2	Thionins	43
3.1.3	Plant defensins	44
3.1.4	Chitin-binding peptides	45
3.1.5	Miscellaneous AMPs from plants	48
3.1.6	Non-ribosomal antimicrobial peptides	49
3.2	Cyclotides	49
3.2.1	Diversity of plant cyclotides	49
3.2.2	Detection and isolation of cyclotides	54
3.2.3	Cyclotide biosynthesis	54
3.2.4	Biological activities of cyclotides	56
3.2.5	Cyclotide engineering and mass production	62
3.3	Concluding Remarks and Perspectives	63
PART II: EXPANDING THE PEPTIDE SPACE: PREDICTION METHODS, DESIGN STRATEGIES AND PEPTIDOMIMETICS		
4	Database-aided Prediction and Design of Novel Antimicrobial Peptides	72
	<i>Guangshun Wang</i>	
4.1	Database-aided Antimicrobial Peptide Prediction	73
4.1.1	Prediction based on mature peptides	73
4.1.2	Prediction based on highly conserved propeptide sequences	75
4.1.3	Prediction based on both propeptides and mature peptides	75
4.1.4	Prediction based on processing enzymes	76
4.1.5	Genomic context-based bacteriocin prediction	76
4.2	Database-aided Peptide Design and Improvement	76
4.2.1	Database screening for HIV inhibitory antimicrobial peptides	76
4.2.2	Sequence shuffling is a primitive combinatorial approach	77
4.2.3	The hybrid approach and grammar-based peptide design	78
4.2.4	<i>De novo</i> peptide design	78
4.2.5	Database-aided enhancement of peptide anti-HIV activity	80
4.3	Strategies for Improving Cell Selectivity of AMPs	80
4.4	Strategies for Improving Peptide Stability to Proteases	82
4.5	Concluding Remarks	82

5	Discovery of Novel Antimicrobial Peptides Using Combinatorial Chemistry and High-throughput Screening	87
	<i>William C. Wimley</i>	
5.1	The Interfacial Activity Model of AMP Activity	87
5.2	Combinatorial Chemistry Methods	88
5.2.1	Overview of library synthesis	88
5.2.2	Non-indexed methods	89
5.2.3	Indexed methods	90
5.3	High-throughput Screening	90
5.3.1	Biological assays	90
5.3.2	Selection of broad-spectrum peptide antibiotics	92
5.3.3	Non-biological assays	94
5.4	Accomplishments	97
5.4.1	Beyond high-throughput screening	97
5.5	Future Directions	98
6	Chemical Mimics with Systemic Efficacy	100
	<i>Amram Mor</i>	
6.1	Introduction	100
6.2	<i>De Novo</i> -designed Rigid Peptidomimetics	102
6.2.1	Hairpin-shaped peptides	102
6.2.2	Peptoids	103
6.2.3	Arylamides	103
6.3	Acyl-lysyl Oligomers	104
6.3.1	Design	104
6.3.2	Structure–activity relationships	104
6.3.3	Antibacterial properties	107
6.3.4	Antiparasital properties	109
6.4	Concluding Remarks and Perspectives	110
PART III: BIOPHYSICS, STRUCTURAL BIOLOGY AND MECHANISM OF ACTION OF ANTIMICROBIAL PEPTIDES		
7	Biophysical Analysis of Membrane-targeting Antimicrobial Peptides: Membrane Properties and the Design of Peptides Specifically Targeting Gram-negative Bacteria	116
	<i>Richard M. Epanand and Raquel F. Epanand</i>	
7.1	Differences in Chemical Composition and Molecular Organization of Gram-positive and Gram-negative Bacteria	116
7.2	Role of Bacterial Membrane Lipid Composition in Antimicrobial Sensitivity	118
7.3	Antimicrobial Agents that Target the Outer Membrane of Gram-negative Bacteria	119
7.4	Antimicrobial Agents that Promote Clustering of Anionic Lipids	120
7.4.1	Evidence for lipid clustering	120
7.4.2	Bacterial species specificity of toxicity	121
7.4.3	Putative mechanism of action	124
7.4.4	Properties of antimicrobial agents that favour clustering	125
7.4.5	Sources of energy to account for clustering and entropy of demixing	125
7.5	Concluding Remarks and Perspectives	125

8	Non-membrane Targets of Antimicrobial Peptides: Novel Therapeutic Opportunities?	128
	<i>Ju Hyun Cho and Sun Chang Kim</i>	
8.1	Introduction	128
8.2	Buforin II: α -Helical AMP with Single Proline Residue Binding to Nucleic Acids	130
8.3	PR-39 and Indolicidin: Mammalian Proline-rich Peptides Inhibiting Macromolecule Synthesis and Cell Division	131
8.4	Apidaecin, Drosocin and Pyrrolicorin: Short, Insect Proline-rich Peptides Binding to Heat-shock Protein DnaK	133
8.5	Concluding Remarks and Perspectives	136
9	Structural Studies of Antimicrobial Peptides Provide Insight into Their Mechanisms of Action	141
	<i>Guangshun Wang</i>	
9.1	Human Defensins and Cathelicidins	141
9.2	Bacterial Expression and Purification of Antimicrobial Peptides	143
9.3	Structural Studies of Membrane-targeting Antimicrobial Peptides	146
9.3.1	Membrane-mimetic models	146
9.3.2	NMR methods	147
9.3.3	Three-dimensional structures of antimicrobial peptides	149
9.3.4	Interactions of antimicrobial peptides with bacterial membranes by NMR spectroscopy	155
9.3.5	Structural basis of peptide selectivity	159
9.4	Structure-based Peptide Engineering	159
9.5	Concluding Remarks and Perspectives	160
PART IV: NOVEL THERAPEUTIC STRATEGIES TO BOLSTER HOST DEFENCE		
10	Lung Infection: Shifting the Equilibrium Towards the Free and Active Form of Human LL-37 and the Design of Alternative Antimicrobial Agents	169
	<i>Paul A. Janmey and Robert Bucki</i>	
10.1	Introduction	169
10.1.1	Electrostatic properties of LL-37	169
10.1.2	Interaction of polyvalent cations with linear polyelectrolytes	170
10.2	Production of Anionic Polyelectrolytes by Host and Microbial Sources	171
10.3	Sequestration and Inactivation of LL-37 by DNA and F-actin	172
10.4	Releasing LL-37 from Polyelectrolyte Bundles	172
10.4.1	Severing polymers with DNase, gelsolin and alginase	173
10.4.2	Destabilizing bundles with small multivalent anions	174
10.5	Designing Antimicrobial Agents Resistant to Inactivation by Polyelectrolytes	174
10.5.1	Cationic steroids: minimizing and redistributing charge	175
10.5.2	Increasing the hydrophobicity of antimicrobial agents	175
10.6	Possible Therapeutic Use	175
10.6.1	Selective use in some body fluids and not others	175
10.6.2	Stimulation of host cells	176
10.7	Conclusion	176

11 Role of Vitamin D in the Enhancement of Antimicrobial Peptide Gene Expression	181
<i>John H. White and Ari J. Bitton</i>	
11.1 Vitamin D	181
11.2 Early History of Vitamin D	181
11.3 Vitamin D Deficiency	182
11.4 Vitamin D Signalling and Mechanisms of Action	182
11.5 Overview of Vitamin D and Immune System Regulation	184
11.6 Vitamin D as a Regulator of Antimicrobial Peptide Gene Expression	185
11.7 Antimicrobial Peptides	185
11.8 Regulation of <i>DEFB2/hBD-2</i> Expression by 1,25D	186
11.9 1,25D Regulation of <i>LL-37</i> is Human and Primate Specific	187
11.10 Broader Physiological and Pathophysiological Implications of the Regulation of <i>LL-37</i> Expression by 1,25D	188
11.11 Therapeutic Role for Vitamin D Analogues	190
12 Fine Tuning Host Responses in the Face of Infection: Emerging Roles and Clinical Applications of Host Defence Peptides	195
<i>Matthew L. Mayer, Donna M. Easton and Robert E.W. Hancock</i>	
12.1 Mammalian Host Defence (Antimicrobial) Peptides	196
12.1.1 Defensins	196
12.1.2 Cathelicidins	197
12.2 The Role of Endogenous Host Defence Peptides in the Response to Infection	198
12.2.1 Natriuretic peptides	201
12.3 Potential Therapeutic Uses beyond Anti-infective Activity	202
12.3.1 Adjuvant potential	204
12.3.2 Wound-healing activity	205
12.4 Recent Clinical Advances in Therapeutic Application of Host Defence Peptides	206
12.5 Innate Defence Regulators as Anti-infective Therapeutics	208
12.6 Rational Design of Immunomodulatory Peptides	209
12.7 Limitations and Challenges	209
12.8 Conclusions	211
Index	221